Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in and
1 other channel

Journal Scan / Research · {not yet published}

Next-Generation Oral SERD Camizestrant vs Fulvestrant in Postmenopausal ER+/HER2− Advanced Breast Cancer

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

The Lancet Oncology
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
Lancet Oncol 2024 Nov 01;25(11)1424-1439, M Oliveira, D Pominchuk, Z Nowecki, E Hamilton, Y Kulyaba, T Andabekov, Y Hotko, T Melkadze, G Nemsadze, P Neven, V Vladimirov, C Zamagni, H Denys, F Forget, Z Horvath, A Nesterova, M Ajimi, B Kirova, T Klinowska, JPO Lindemann, D Lissa, A Mathewson, CJ Morrow, Z Traugottova, R van Zyl, E Arkania

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.